- Home
- STTK vs GNS Comparison
STTK vs GNS Comparison
Compare STTK & GNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- GNS
- Stock Information
- Founded
- STTK 2016
- GNS 2002
- Country
- STTK United States
- GNS Singapore
- Employees
- STTK N/A
- GNS N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- GNS Other Consumer Services
- Sector
- STTK Health Care
- GNS Real Estate
- Exchange
- STTK Nasdaq
- GNS Nasdaq
- Market Cap
- STTK 83.8M
- GNS 72.9M
- IPO Year
- STTK 2020
- GNS 2022
- Fundamental
- Price
- STTK $1.92
- GNS $1.08
- Analyst Decision
- STTK Hold
- GNS
- Analyst Count
- STTK 6
- GNS 0
- Target Price
- STTK $2.67
- GNS N/A
- AVG Volume (30 Days)
- STTK 1.6M
- GNS 2.6M
- Earning Date
- STTK 08-14-2025
- GNS 04-30-2025
- Dividend Yield
- STTK N/A
- GNS N/A
- EPS Growth
- STTK N/A
- GNS N/A
- EPS
- STTK N/A
- GNS N/A
- Revenue
- STTK $2,997,000.00
- GNS $7,912,718.00
- Revenue This Year
- STTK N/A
- GNS $62.23
- Revenue Next Year
- STTK N/A
- GNS $69.63
- P/E Ratio
- STTK N/A
- GNS N/A
- Revenue Growth
- STTK N/A
- GNS N/A
- 52 Week Low
- STTK $0.69
- GNS $0.21
- 52 Week High
- STTK $3.95
- GNS $1.92
- Technical
- Relative Strength Index (RSI)
- STTK 72.13
- GNS 58.49
- Support Level
- STTK $1.68
- GNS $0.72
- Resistance Level
- STTK $2.04
- GNS $0.85
- Average True Range (ATR)
- STTK 0.19
- GNS 0.10
- MACD
- STTK 0.09
- GNS 0.02
- Stochastic Oscillator
- STTK 89.29
- GNS 91.26
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.